Current outlook of cardiac stem cell therapy towards a clinical application

Heart

Volumn 99, Issue 23, 2013, Pages 1772-1784

  Takashima, Shin Ichiro ^a   Tempel, Dennie ^a   Duckers, Henricus J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; CHEMOKINE RECEPTOR CXCR4; FIBROBLAST GROWTH FACTOR 2; GRANULOCYTE COLONY STIMULATING FACTOR; HEPARIN; HIRULOG; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; PLACEBO; SCATTER FACTOR; SOMATOMEDIN C; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; VASCULOTROPIN 165;

ACUTE HEART INFARCTION; ADIPOSE DERIVED STEM CELL; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CARDIOVASCULAR DISEASE; CATHETER; CELL TRANSDIFFERENTIATION; CHAGAS DISEASE; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CYTOKINE RELEASE; DRUG EFFECT; EMBRYONIC STEM CELL; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART TRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; ISCHEMIC CARDIOMYOPATHY; ISCHEMIC HEART DISEASE; MESENCHYMAL STEM CELL TRANSPLANTATION; MONONUCLEAR CELL; MYOBLAST; NONHUMAN; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; THERAPY EFFECT; TISSUE REGENERATION; VASCULAR DERIVED STROMAL FRACTION;

INTERVENTIONAL CARDIOLOGY; MYOCARDIAL ISCHAEMIA AND INFARCTION (IHD);

ALLOGRAFTS; AUTOGRAFTS; EMBRYONIC STEM CELLS; HEART; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MYOBLASTS; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; PLURIPOTENT STEM CELLS; REGENERATION; STEM CELL TRANSPLANTATION; TIME FACTORS;

EID: 84888052095     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-303308     Document Type: Article

References (21)

1. Bergmann O, Bhardwaj RD, Bernard S, et al. Evidence for cardiomyocyte renewal in humans. Science 2009;324:98-102.
2. Murry CE, Soonpaa MH, Reinecke H, et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 2004;428:13-15.
3. Gnecchi M, Zhang Z, Ni A, et al. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 2008;103:1204-19.
4. Wu SM, Chien KR, Mummery C. Origins and fates of cardiovascular progenitor cells. Cell 2008;132:537-43.
5. Zimmet H, Porapakkham P, Porapakkham P, et al. Short- and long-term outcomes of intracoronary and endogenously mobilized bone marrow stem cells in the treatment of ST-segment elevation myocardial infarction: a meta-analysis of randomized control trials. Eur J Heart Fail 2012;14:91-105.
6. Choi Y-H, Kurtz A, Stamm C. Mesenchymal stem cells for cardiac cell therapy. Hum Gene Ther 2011;22:3-17.
7. Patel SA, Sherman L, Munoz J, et al. Immunological properties of mesenchymal stem cells and clinical implications. Arch Immunol Ther Exp 2008;56:1-8.
8. Gimble JM, Katz AJ, Bunnell BA. Adipose-derived stem cells for regenerative medicine. Circ Res 2007;100:1249-60.
9. Hare JM, Traverse JH, Henry TD, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 2009;54:2277-86.
10. Hou D, Youssef EA-S, Brinton TJ, et al. Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: implications for current clinical trials. Circulation 2005;112(9 Suppl):I150-6.
11. Schächinger V, Erbs S, Elsässer A, et al. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur Heart J 2006;27:2775-83.
12. Traverse JH, Henry TD, Ellis SG, et al. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA 2011;306:2110-19.
13. van der Spoel TIG, Jansen of Lorkeers SJ, Agostoni P, et al. Human relevance of pre-clinical studies in stem cell therapy: systematic review and meta-analysis of large animal models of ischaemic heart disease. Cardiovasc Res 2011;91:649-58.
14. Wollert KC, Meyer GP, Lotz J, et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 2004;364:141-8.
15. Lipinski MJ, Biondi-Zoccai GGL, Abbate A, et al. Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a collaborative systematic review and meta-analysis of controlled clinical trials. J Am Coll Cardiol 2007;50:1761-7.
16. Houtgraaf JH, den Dekker WK, van Dalen BM, et al. First experience in humans using adipose tissue-derived regenerative cells in the treatment of patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 2012;59:539-40.
17. Duckers HJ, Houtgraaf J, Hehrlein C, et al. Final results of a phase IIa, randomised, open-label trial to evaluate the percutaneous intramyocardial transplantation of autologous skeletal myoblasts in congestive heart failure patients: the SEISMIC trial. EuroIntervention 2011;6:805-12.
18. Povsic TJ, O'Connor CM, Henry T, et al. A double-blind, randomized, controlled, multicenter study to assess the safety and cardiovascular effects of skeletal myoblast implantation by catheter delivery in patients with chronic heart failure after myocardial infarction. Am Heart J 2011;162:654-62.
19. Pokushalov E, Romanov A, Chernyavsky A, et al. Efficiency of intramyocardial injections of autologous bone marrow mononuclear cells in patients with ischemic heart failure: a randomized study. J Cardiovasc Transl Res 2010;3: 160-8.
20. Trachtenberg B, Velazquez DL, Williams AR, et al. Rationale and design of the transendocardial injection of autologous human cells (bone marrow or mesenchymal) in chronic ischemic left ventricular dysfunction and heart failure secondary to myocardial infarction (TAC-HFT) trial: a randomized, double-blind. Am Heart J 2011;161:487-93.
21. Makkar RR, Smith RR, Cheng K, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet 2012;379:895-904.